Evidence memo

MOTS-c

Also tracked as: Mitochondrial-derived peptide MOTS-c

A mitochondria-derived peptide with mechanistic metabolic interest and limited human outcome evidence.

Preclinical Safety watch

Evidence status

High interest / low certainty. Evidence level: Preclinical.

Whether mitochondrial-derived peptide biology translates into clinically meaningful human metabolic or aging outcomes.

MOTS-c connects energy metabolism, exercise biology, and longevity narratives in a way that attracts strong attention.

Mechanistic and preclinical signals are more developed than controlled human outcome evidence.

Clinical outcomes, safety, product identity, and whether biomarker movement would mean anything patients can feel or measure clinically.

Mechanistic plausibility is not clinical proof. Product identity matters especially for non-approved peptide products.

Human trials with clinical endpoints, safety reporting, and better distinction between endogenous biology and exogenous products.

Interesting biology, thin clinical translation.

Peer-reviewed journal

Diabetology & Metabolic Syndrome · 2024

Association and mechanistic literature; clinical-outcome translation remains unsettled.

FDA

U.S. Food and Drug Administration · Current FDA page

Regulatory source for compounding-safety watch items; status should be rechecked before publication.